How to dose extended-release carbidopa-levodopa capsules (IPX203) in Parkinson’s disease patients: Experience from the Phase 3 clinical trial
Objective: To provide guidance on dosing of IPX203 based on clinical trial experience. Background: IPX203 is an extended-release, oral carbidopa-levodopa (CD-LD) formulation designed to rapidly…Initial 24-hours Levodopa Carbidopa Intestinal Gel initiation in advanced Parkinson’s disease
Objective: To evaluate the profile of those patients with advanced Parkinson’s Disease (APD) in which we decided to use continuous 24-hour administration of Levodopa Carbidopa…Improvement in motor symptoms and quality of life in patients with an earlier stage of advanced Parkinson’s disease treated with foslevodopa/foscarbidopa subcutaneous 24 hour infusion
Objective: To evaluate whether treatment with foslevodopa/foscarbidopa (LDP/CDP), a continuous (24‑hour/day) subcutaneous infusion of carbidopa/levodopa prodrugs, improves motor fluctuations and quality of life (QoL) in…A randomized, phase 2a, double-blind, placebo-controlled clinical trial with NE3107 adjunctive to carbidopa/levodopa in patients with Parkinson’s disease
Objective: To evaluate the motor effects of NE3107 treatment in patients with levodopa-treated Parkinson’s disease (PD) experiencing motor fluctuations. Background: NE3107 is an oral, blood-brain…Foslevodopa/foscarbidopa subcutaneous infusion shows similar infusion site reaction severity score across range of infusion rates in patients with Parkinson’s disease
Objective: Characterize the relationship between foslevodopa/foscarbidopa infusion rate and infusion site reaction (ISR) score in patients with Parkinson’s disease (PD) Background: As PD progresses, motor…Levodopa-entacapone-carbidopa-infusion treatment in Parkinson’s disease: A six-month follow-up study
Objective: Objectives of this study were to evaluate changes in medication, adverse events and early discontinuations of levodopa-entacapone-carbidopa-intestinal-gel (LECIG) treatment in advanced Parkinson’s disease (PD).…Common oscillatory patterns between Parkinson’s disease and heroin dependent patients: a resting-state EEG study
Objective: We aimed to compare resting-state EEG oscillations between Parkinson’s disease (PD) patients during their ON and OFF Dopamine Replacement Therapy (DRT) states, heroin-dependent (HD)…Continuous algorithmic insights into PD motor symptoms and individual treatment response
Objective: To quantify the short-duration levodopa response using high resolution data derived from a wrist sensor and processed with advanced deep learning methods Background: The…Early versus late levodopa administration in Parkinson’s disease: Comparative study
Objective: To evaluate levodopa-sparing strategy in terms of motor decline and complications. Background: Levodopa remains the gold standard for treatment of Parkinson’s disease(PD), as it…The Short Duration Response and Long Duration Response to L-Dopa are Needed to Restore Vigor-Motivation Coupling in Parkinson Disease
Objective: To assess the relationship between the Short Duration Response (SDR) and Long Duration Response (LDR) to L-Dopa therapy in Parkinson disease (PD) and restoration…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 57
- Next Page »